+612 9045 4394
 
CHECKOUT
Antiviral Chemotherapy : Antiviral Chemotherapy 5 New Directions for Clinical Application and Research v. 5 - John Mills

Antiviral Chemotherapy

Antiviral Chemotherapy 5 New Directions for Clinical Application and Research v. 5

By: John Mills (Editor), Paul Volberding (Editor), Lawrence Corey (Editor)

Hardcover

Published: 31st March 1999
Ships: 7 to 10 business days
7 to 10 business days
RRP $609.99
$422.25
31%
OFF
or 4 easy payments of $105.56 with Learn more

Scientists and clinicians attending the last "New Directions in Antiviral Therapy" conference in late 1994 could hardly have predicted the revolution in the management of patients with HIV infection that has occurred since. Two new classes of antiretrovirals have been licensed, the second-site RT inhibitors and the protease inhibitors; the long in­ cubation period of active HIV infection, when the infection is clinically latent, is now un­ derstood to be a period of intense viral replication and turnover of CD4 lymphocytes; measurements of HI V RNA concentration in plasma have been shown to be essential tools for monitoring the course of HIV infection, deciding when to treat, and assessing the re­ sults of treatment; and finally, combinations of antiretrovirals, particularly combinations including protease inhibitors, have been shown to have dramatically beneficial effects on patients with HIV infection. These advances, coupled with new drugs for the management of herpesvirus infections, have made dramatic differences in the quality and length of life of HIV-infected patients. Additional advances have been made since 1994 in the prevention or management of influenza virus (zanamavir), respiratory syncytial virus (palvizumab), hepatitis B virus (lamivudine and famciclovir), and enterovirus infections (pleconaril). It is difficult to re­ member that only slightly more than a decade ago there were only a handful of antiviral agents available (none of which were antiretrovirals), and a number of those were either highly toxic, of dubious efficacy, or both.

Overview of HBV Therapyp. 1
Lamivudine Therapy of Chronic Hepatitis Bp. 11
Famciclovir Update: Chronic Hepatitis Bp. 23
Current Status of Antiviral Therapy for Chronic Hepatitis Cp. 29
Prevention and Treatment of Respiratory Syncytial Virus Infectionsp. 39
Update on Influenza and Rhinovirus Infectionsp. 55
Pleconaril: A Broad Spectrum Antipicornaviral Agentp. 69
Management of CMV Infections in HIV-Infected Patientsp. 77
Management of Cytomegalovirus Infections in Blood and Marrow Transplant Recipientsp. 89
Cidofovir: Review of Current and Potential Clinical Usesp. 111
Oral Ganciclovirp. 121
Development of Novel Benzimidazole Riboside Compounds for Treatment of Cytomegalovirus Diseasep. 129
Famciclovir/Penciclovirp. 135
Valaciclovir Updatep. 149
Therapeutic Approaches to the Management of Herpes Zosterp. 159
Management of Varicella-Zoster Virus Infections in Childrenp. 167
Failure of HIV-1 Protease Inhibitors to Fully Suppress Viral Replication: Implications for Salvage Therapyp. 175
New Reverse Transcriptase Inhibitorsp. 183
HIV Viral Load Monitoringp. 199
Post-Exposure Prophylaxis for HIVp. 213
Antiretroviral Therapy in Primary HIVp. 223
Initial Treatment for HIV Infection: When, Why, and with What?p. 229
Strategies for Second-Line Antiretroviral Therapy in Adults with HIV Infectionp. 239
Indexp. 267
Table of Contents provided by Blackwell. All Rights Reserved.

ISBN: 9780306461071
ISBN-10: 0306461072
Series: Advances in Experimental Medicine and Biology
Audience: Professional
Format: Hardcover
Language: English
Number Of Pages: 271
Published: 31st March 1999
Publisher: SPRINGER VERLAG GMBH
Country of Publication: US
Dimensions (cm): 26.67 x 17.15  x 1.91
Weight (kg): 0.61